Scientists from the University of Eastern Finland have identified alterations occurring in the human brain that signal the early stages of this common neurogenerative disease.
The FDA’s review of drug and biological products in this medication class is critical, as a brain impairment impacts between 6.5% and 7.9% of adults in the United States.
There have been significant evidence-based literature updates regarding the management of acute ischemic stroke (AIS) in adult patients; these are discussed in a 2018 guideline update.
According to the CDC’s Behavioral Risk Factor Surveillance System 2013, nearly 71% of adults with atherosclerotic cardiovascular disease use aspirin regularly.